Next Article in Journal
Residue–Residue Interaction Prediction via Stacked Meta-Learning
Next Article in Special Issue
Type I Interferons Enhance the Repair of Ultraviolet Radiation-Induced DNA Damage and Regulate Cutaneous Immune Suppression
Previous Article in Journal
Proteomics of Homeobox7 Enhanced Salt Tolerance in Mesembryanthemum crystallinum
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 12
10.3390/ijms22126395
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances

by
Strahil Strashilov
1,* and
Angel Yordanov
2
1
Department of Plastic Restorative, Reconstructive and Aesthetic Surgery, University Hospital “Dr. Georgi Stranski”, Medical University Pleven, 5800 Pleven, Bulgaria
2
Clinic of Gynecologic Oncology, University Hospital “Dr. Georgi Stranski”, Medical University Pleven, 5800 Pleven, Bulgaria
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(12), 6395; https://doi.org/10.3390/ijms22126395
Submission received: 17 May 2021 / Revised: 9 June 2021 / Accepted: 11 June 2021 / Published: 15 June 2021
(This article belongs to the Special Issue Immunomodulation of Skin Cancer)
Browse Figures
Review Reports Versions Notes

Abstract

:
Melanoma develops from malignant transformations of the pigment-producing melanocytes. If located in the basal layer of the skin epidermis, melanoma is referred to as cutaneous, which is more frequent. However, as melanocytes are be found in the eyes, ears, gastrointestinal tract, genitalia, urinary system, and meninges, cases of mucosal melanoma or other types (e.g., ocular) may occur. The incidence and morbidity of cutaneous melanoma (cM) are constantly increasing worldwide. Australia and New Zealand are world leaders in this regard with a morbidity rate of 54/100,000 and a mortality rate of 5.6/100,000 for 2015. The aim of this review is to consolidate and present the data related to the aetiology and pathogenesis of cutaneous melanoma, thus rendering them easier to understand. In this article we will discuss these problems and the possible impacts on treatment for this disease.

1. Introduction

The term melanoma was first used in 1812 by René Laennec to describe a case of metastatic dissemination of the disease [1]. Cutaneous melanoma (cM) develops from malignant transformations of pigment-producing melanocytes in the basal layer of the skin epidermis. Non-cutaneous melanoma arises from malignantly transformed melanocytes in the uvea [2,3], gastrointestinal tract [4,5], genitalia [6,7], urinary system [8,9], meninges [10,11], etc. The incidence and morbidity of cM are constantly increasing worldwide. Australia and New Zealand are world leaders in this regard with a morbidity rate of 54/100,000 and a mortality rate of 5.6/100,000 for 2015 [12].
The aim of this review is to consolidate and present the data related to aetiology and pathogenesis of cutaneous melanoma, thus rendering them easier to understand. In this article we will discuss these problems and the possible impacts on treatment for this disease.

2. Aetiology

The aetiological factors for the development of the cutaneous melanoma are related to both the human body and the environment (Table 1).

2.1. Ultraviolet Radiation

Exposure to ultraviolet radiation is the leading risk factor for the development cM. Both natural sunlight and artificial lighting systems are ultraviolet radiation sources [13]. The light spectrum of this radiation includes electromagnetic waves with a length between 200 and 400 nm. The radiation of the UVB wavelength between 290 and 320 nm is the most carcinogenic for the skin [14,15]. Its waves are absorbed at the greatest extent by the nuclear proteins and acids of the skin cells, including melanocytes. They interact directly through oxidative stress, which disrupts the melanocytes. [16,17]. There is also an indirect damaging effect of these rays by the mechanisms of DNA repair. This irreparable damage promotes the occurrence of numerous mutations, inducing carcinogenesis with the transformation of normal cells into cancerous cells [18,19].

2.2. Skin Phototype

Different skin phototypes are being described and they are dividing the skin of people into six subtypes—I to IV. People with skin phototypes I and II have fair skin, blond or red hair, many freckles, and blue eyes and are most sensitive to ultraviolet exposure. Therefore, these individuals are subject to a higher risk of developing melanoma of the skin due to lower resistance to UVB rays [20,21].

2.3. Pigmented Nevi

Pigmented nevi represent benign proliferations of the melanocytes in the skin (Figure 1).
Pigmented nevi usually remains unchanged in size and behaviour or disappears during life [22]. Approximately 33% of melanomas are derived directly from pigmented nevi [23]. People with multiple different in colour or different in shape pigmented nevi are more prone to developing cM. They are, additionally, found to possess skin phototypes I and II more frequently [24].

2.4. Use of Pesticides

People working with herbicides are also more likely to develop acral melanoma on the palms of the hands and the soles of the feet. The most commonly used herbicides that result in this disease are the following: dichlorprop, atrazine, propanil, paraquat, diquat, thiocarbamates, alachlor, acetochlor, metolachlor, imazethapyr, pendimethalin, and glyphosate. The incidence of people with acral melanoma who have used these herbicides at home is higher than in people who do not use them [25].

2.5. Prolonged Sun Exposure and Sunburn

The World Health Organization declared that prolonged sun exposure and sunburn are carcinogenic to humans. Excessive sun and ultraviolet exposure and frequent sunburns, especially at a younger age, significantly increases the risk of developing cM. [26,27].

2.6. Geographical Location

The incidence of cMM varies depending on the geographic location. The highest incidence in the world occurs in Australia and New Zealand [12]. The highest incidence in Europe occurs in Northern Europe and especially Scandinavia. The lowest incidence of cM in Europe is in Eastern and Southern Europe [28].

2.7. Genetic Factors

cM develops as a result of the grouping of multiple abnormalities in the melanocyte genetic pathways. They initiate cell proliferation and cessation of apoptosis as a normal response to DNA damage [29,30]. Mutations in various genes are the main driving force in this process. The first gene that is specifically altered in 15–20% of cases is NRAS [31,32]. The mutation is found mainly in melanomas, which is caused by prolonged exposure to sunlight, in the nodular form and in melanoma with a greater thickness (>1 mm) [33].
Mutation in the BRAF gene is another mutation frequently occurring in cM. It accounts for about 50% of the cases. BRAF kinase plays a role in the regulation of the signalling pathway between mitogen-activated protein kinase and extracellular signal-regulated kinase (MAP/ERK), which controls the cell division and differentiation. As a result, uncontrolled division of melanocytes occurs and results in a development of melanoma [34,35]. This mutation is often found in dysplastic nevi that, once again, demonstrates its role in the carcinogenesis of the disease. It is also found in melanoma cells that are submitted to a prolonged exposure to UV radiation [34].
The PTEN gene, which encodes a tumour suppressor protein, is a third gene for which mutations may be associated with the development of melanoma. When damaged, the tumour suppressor protein cannot accomplish its role and continuous cell proliferation begins. This mutation is found in 10–20% of patients with primary melanoma [31,36,37].

2.8. Heredity

There are several genes (CDKN2A, CDK4, POT1, ACD, TERF2IP, TERT, BRCA 1 and 2, BAP 1, MITF, TP53, XPC, XPD, XPA, and PTEN) for which mutations may be inherited and results in hereditary melanoma [38]. CDKN2A, located on chromosome 9 is gene for which damage is associated with a disorder in the control of cell division. CDKN2A mutations are most common in patients with heredity melanoma. It is found in 20% of the families with skin melanoma history. The CDK4 gene is located on chromosome 12 and is also involved in regulating cell division. Mutations of this gene are tracked only in isolated cases of cM. CDKN2A mutations with p14 loss result in cutaneous melanoma but are also found in pancreatic carcinoma. This explains why some families have an increased risk of developing these two neoplasms [39,40,41,42,43,44,45,46,47]. Mutations in the somatic gene TP53 encoding protein 53 (p53) also results in the development of heredity melanoma. In its normal state, p53 functions as a tumour suppressor, permitting damaged cells to recover and halts progression to cancer. In the case of gene mutations, this protein is unable to execute its function [39].

2.9. Immunosuppressive Conditions

Systemic immunosuppression with cyclosporine and sirolimus in renal transplantation results in the inactivation of tumour suppressors such as p53 and PTCH and the activation of the proto-oncogenes H-ras, K-ras, and N-ras. All this results in DNA damage and retention genetic mutation and therefore induces the development and spread of skin melanoma [48]. Patients with immunosuppressive diseases such as AIDS are more likely to develop skin melanoma as the continuous immunosuppression ineffectively protects the organism from occurrence and the progression of many solid tumours [49,50].

2.10. Non-Melanoma Skin Cancer

Patients with squamous cell carcinoma, basal cell carcinoma, and actinic keratosis have an increased risk of developing melanoma of the skin. This is most likely due to various genetic factors and prolonged exposure to sunlight [51,52].

3. Pathogenesis of Cutaneous Melanoma

The production of melanin by melanocytes is their unique feature. In turn, melanin has a complex of anti-oxidant and pro-oxidant properties [16,53]. Its conversion from an antioxidant to a pro-oxidant agent under the influence of various etiological factors such as UV radiation, heavy metals, herbicides, etc., is the critical and earliest pathogenetic event that initiates carcinogenesis. The pro-oxidant action of the melanin results in an increase in the levels of intracellular oxygen radicals, which in turn causes damage to the DNA molecule of the melanocyte. The result of these mutations is excessive activation of various cell signalling pathways and results in the uncontrolled proliferation, dedifferentiation, and immortalization of specific cell types [54].
In 2018, the WHO presented the latest version of the generalized classification of the pathways for the genesis of cutaneous, mucosal, and uveal melanomas based on the main aethiological factor (cumulative sun damage), clinical and pathological characteristics of the precursor lesions, and the genetic aberations which accompany their development. Nodular cutaneous melanoma occupies a special place in this classification because all or most of these pathways refer to it. The pathways which refer to the remaining skin and mucosal melanomas are eight and they are divided into two major groups. The first group includes the melanomas associated with cumulative solar damage (CSD) and consists of three pathways—I, II, III (Table 2).
The second group includes the melanomas that are not associated with cumulative solar damage (no CSD) and consists of five pathways—IV, V, VI, VII, VIII (Table 3) [55].
This classification clearly and accurately describes the pathogenesis of this disease and includes all known genetic mutations involved in it. The exact location of these abnormalities in the various pathogenetic, signaling, and cellular pathways is presented in detail below.

3.1. MAPK Pathway

The mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation, growth, and migration and is activated in almost all types of melanomas. This pathway is active under normal conditions, but in the cases of melanoma it is associated with excessive activation [56]. It is activated after binding of growth factors to tyrosine kinase receptors. Stimulation of these receptors activates Ras family proteins—monomeric G proteins (NRAS)—causing the cascade activation of serine/threonine kinases (BRAF) and results in the activation of ERK kinase (also known as MAPK). Serine/threonine kinase activates transcription factors, thereby intensifying the transcription of genes involved in cell growth, proliferation, and migration (Figure 2).
In 80% of the cases of melanoma or melanocytic nevi, mutations in NRAS or BRAF genes are observed, which confirms the crucial role of the MAPK pathway [56]. Activating mutations of BRAF serine/threonine kinase (40–50%) and G protein NRAS (15–20%) are the main aberrations leading to the MAPK pathway activation in melanomas [57].
Understanding of the MAPK pathway has led to the development of targeted therapy with BRAF inhibitors alone or in combination with MEK inhibitors (vemurafenib + cobimetinib; dabrafenib + trametinib) for patients with activating mutations in BRAF [35,58,59].

3.2. BRAF

BRAF is a serine/threonine kinase that is activated directly by RAS and is strongly expressed in melanocytes, neural tissue, testes, and hematopoietic cells. BRAF has been found in phosphorylate and activates MEK (a kinase component of the MAPK pathway), which in turn activates ERK (MAPK) by phosphorylation and thus stimulates growth and transformation. This is crucial for the pathogenesis of melanomas [35,59,60]. The conversion of thymidine to adenine (T → A) is the most common mutation in the BRAF gene (~70%). It results in the substitution of valine with glutamate (V600E) in the protein molecule, resulting in the activation of its kinase domain. These mutations indirectly results in BRAF activation by disrupting the normal intramolecular interactions that hold BRAF in inactive configurations [35,57]. Mutations in the BRAF gene (V600E) are more common in melanoma that develops in parts of the body that are exposed to solar radiation. Although BRAF mutations may be associated with sun exposure, the transversion (T → A), as mentioned earlier, is not classically related to UV exposure [35,60]. Other amino acid substitutions in the protein are possible, such as those observed in V600K mutations (representing ~20% of BRAF mutations in melanoma). They are mainly found in melanoma patients exposed to chronic sun exposure. BRAF V600 mutations represent an early event in the development of melanoma. They are less common in its initial stages—in 10% of the cases with radial growth—and in 6% of in situ melanomas. However, they are very common in metastatic melanoma. These mutations occur in approximately 80% of the benign and the dysplastic nevi, but they alone are not sufficient for the development of cutaneous melanoma [57].
Interestingly, BRAF (V600E) mutation in nevi involves initial cell proliferation and is followed by oncogene-induced ageing, most likely as a part of the accumulation of p16 INK4a; in melanoma BRAF (V600E), mutations only induce uncontrolled proliferation. Many nevi and primary melanomas are polyclonal and contain cells with mutated BRAF and wild-type cells (without BRAF mutation). Metastatic melanomas, on the other hand, are monoclonal [60]. Mutations in BRAF V600E are more common in women and correlate inversely with age [38], while the rate of BRAF V600K mutations increases with age [57].

3.3. RAS

Mutations, leading to increased RAS activity in melanomas also increase cell proliferation, but this occurs significantly less frequently than in other solid tumours [60]. The Q16R mutation is the most common NRAS mutation in melanoma. Somatic NRAS gene mutations may cause increased activity of the NRAS protein, which cannot “shut down”. This results in a serial activation of serine/threonine kinases, stimulating cell cycle progression, cell transformation, and cell survival. The cascade of events can also be caused by overexpression and/or hyperactivation of various growth factor receptors such as c-Met, epidermal growth factor receptor (EGFR), and c-KIT as well as the functional loss of neurofibromatosis type 1 (NF1) tumour suppressor gene, which suppresses NRAS signalling [61,62]. Activating RAS mutations were observed in only 10–20% of melanomas (mostly in amelanotic nodular subtypes), with NRAS mutations being the most common. BRAF mutations only activate the MAPK signalling pathway, while activating NRAS mutations simultaneously activates the MAPK and PI3K pathways [60,62]. NRAS and BRAF mutations have been found to rarely co-occur, indicating that a mutation in one of the two genes is sufficient to activate the MAPK pathway. Activating BRAF mutations are more common in nevus cells (70–80% of dysplastic nevi). NRAS mutations are rare in nevi and are most common in congenital ones. NRAS mutations are often associated with Spitz nevi [60].
The uncontrolled activation of the MAPK signalling pathway in melanomas may be caused by overexpression or hyperactivation of growth factor receptors such as c-Met, c-KIT, and epidermal growth factor receptor (EGFR) [62].

3.4. c-KIT

c-KIT (tyrosine kinase receptor) and its ligand (stem cell factor) play an essential role in melanocyte development [59,63]. c-KIT mutations cause insufficient pigmentation. The results of numerous immunohistochemical studies indicate that the transition from a benign condition to primary or metastatic melanoma is associated with a loss of c-KIT expression. The activating mutations and amplification of KIT genes have been observed in cutaneous melanomas in areas exposed to chronic sun exposure as well as in acral melanomas (of the hands, feet, and nail bed). KIT mutations can activate multiple signalling pathways and the PI3K-AKT pathway in particular. The presence of point mutations in the KIT gene has also been observed in gastrointestinal stromal tumours (GIST). The functional characteristics of these mutations are clinically significant as KIT inhibitors are effective in melanomas, but with a much lower degree of clinical response (10–30%) compared with GIST (>70%) [57,63].

3.5. c-MET and HGF

Overexpression of another tyrosine kinase receptor c-MET and its ligand HGF (hepatocyte growth factor) correlates with melanoma progression. c-MET is known to control a variety of biological functions such as propagation, survival, motility, and invasion. Tumours can grow and metastasize due to dysregulation caused by aberrant c-MET activation. It should be noted that c-MET (tyrosine kinase receptor) may be overactivated in the event of the excessive secretion of its HGF ligand produced by tumour cells or the tumour microenvironment of melanoma. This paracrine effect activates the PI3K-AKT pathway in tumour cells and leads to resistance to MAPK inhibitors [57,64].

3.6. Other Factors

Neurofibromatosis type 1 (NF1) tumour suppressor gene and the negative RAS regulator are other driving factors in the process. NF1 mutations were identified in 5 of 21 tumours without BRAF and NRAS mutations. In the context of BRAF (V600E) mutations, NF1 has been observed to disrupt normal MAPK and PI3K pathways by inhibiting the development and the metastatic spread of melanoma. Inactivating mutations of neurofibromatosis tumour suppressor gene 2 (NF2) have been observed in some melanomas. Initial mutations in NF1 and NF2 genes are associated with hereditary neurofibromatosis. Other somatic mutations of the melanoma cells in MAPK downstream effectors have been identified, such as MAP3K5, MAP3K9, MEK1, and MEK2 [60,65].

3.7. PI3K/PTEN/AKT Pathway (Phosphatidylinositol 3-kinase Pathway)

PI3K-AKT is another critical signalling pathway in the cell. It is involved in the regulation of cell survival, growth, and apoptosis [56,66] (Figure 3).
In carcinomas, this pathway can be genetically driven by activating mutations (e.g., PIK3CA and AKT1) or by functional loss of some of the components of this pathway (e.g., PTEN). PI3 kinases (phosphatidylinositol 3-kinase-lipid kinases) are triggered directly by tyrosine kinase receptor activation or indirectly by RAS. They cause phosphorylation of PIP2 to PIP3 and subsequent phosphorylation of AKT [57,66]. PTEN lipid phosphatase plays an essential role as an agent antagonizing this pathway by converting PIP3 back to PIP2 [67]. Phosphorylation of AKT (serine/threonine protein kinase) results in the phosphorylation of multi-factor proteins that regulate cellular processes (proliferation, survival, motility, angiogenesis, and metabolism). m-TOR is one of these proteins found to be activated in 73% of human melanoma cell lines and very rarely in nevus cells. Increased activation of PI3K signalling is observed in a large number of melanomas, usually triggered by mutations, deletions, and promoter methylation of the coding genes of the PTEN inhibitor [66].

3.8. MITF Signalling

Microphthalmia-associated transcription factor (MITF) is a key regulator that is required for melanocyte differentiation, which may affect malignancy in some melanomas. The most common MITF genetic alteration is amplification, which occurs in 15–20% of melanomas (more common in metastatic melanomas) [68,69]. These changes are thought to occur later in disease progression and are associated with lower 5 year survival [70]. MITF increases the gene expression involved in the cell cycle progression, the cell proliferation, and the cell survival. It is a transcription factor for cellular cyclin-dependent kinase (CDK2), CDK inhibitors p16INK4a, and p21 as well as for the antiapoptotic mitochondrial membrane protein BCL-2 (B-cell lymphoma 2) [71,72]. MITF expression is triggered by the activation of the melanocortin 1-receptor (MC1R), which in turn is activated by the binding of melanocortins (ACTH and α-MSH) [71]. This induces adenylate cyclase activation and the production of c-AMP, which activates protein kinase A (PKA). In turn, PKA activates CREB (cAMP protein-binding response element), which acts as a transcription factor and enhances MITF expression. MITF signalling is also closely related and regulated by MAPK signalling. It has been observed that the mutated oncogene BRAF can regulate MITF expression, thus ensuring protein levels compatible with the proliferation and survival of melanoma cells. Importantly, MITF may also act as an anti-proliferative transcription factor that induces cell cycle arrest. In melanocytes, MITF expression occurs after the binding of the melanocyte-stimulating hormone (MSH) to the melanocortin 1 receptor (MC1R). In this process, MITF targets the genes involved in the regulation of differentiation and pigmentation, distribution, and survival [68,71].

3.9. p53

p53 is the primary tumour suppressor gene, associated with apoptosis. The p53 protein encoded is a major transcription factor and bears crucial responsibility for various stresses such as DNA damage, genome instability, hypoxia, and oncogenic aberrations [73]. Disorders in the control of the cell cycle, genomic instability, and abnormal proliferation are observed during the transformation of melanocytes into melanoma cells. Mutations or deletions of p53 are observed in more than 50% of carcinomas. In melanomas, they occur in only 1–5% of primary melanomas and in 11–25% of metastatic melanomas [74]. The expression of the p53 protein in melanomas is variable [75,76], while it is often absent in nevi. Melanoma often results in the overexpression of this protein than when compared to other tumours. Despite the high expression of p53, melanoma cells are highly resistant to apoptosis. This can be explained by the impaired functionality of the p53 apoptotic pathway [77].

3.10. Hypoxia-Induced Factor (HIF)

An essential factor for tumour development and progression is the environment itself. Human skin is generally hypoxic, which in turn favours melanogenesis [78]. The hypoxic response is primarily mediated by HIF. It activates many genes, associated with angiogenesis, invasion, and metastasis. Hypoxia in the microenvironment of the skin favours melanocyte transformation and tumour growth induced by the PI3K pathway. Inhibition of the HIF gene reduces this process. Tumour hypoxia occurs with melanoma growth due to poor vascularization, which increases HIF and stimulates melanogenesis and melanoma progression, thus being of negative prognostic value [79]. Melanomas located in areas of hypoxia possess the worse prognosis despite treatment [80,81].

3.11. Notch Signalling Pathway

Notch signalling pathway has a substantial potential for the development and maintenance of tissue homeostasis. It includes a family of transmembrane receptors and their ligands, negative and positive modifiers, and transcription factors. In mammals, four receptors and five ligands are known [82]. Notch can function as a tumour promoter or suppressor depending on the type of cells. Its activation through the overexpression of Notch receptor genes 1, 2, and 4 plays a role in melanoma progression and metastasis, which is a function mediated by β-catenin [83,84,85]. Notch 1 signalling pathway is enhanced in melanoma cells. Along with the AKT pathway and the pathway induced by hypoxia, Notch is involved in the transformation of a normal melanocyte into a melanoma cell [86].

3.12. Other Factors Important in the Pathogenesis of Melanoma

Telomerase reverse transcriptase (TERT) is a gene located on chromosome 5p15.33 and encodes the catalytic subunit of telomerase. Telomerase is an enzyme that adds nucleotides to telomeres. In normal cells its activity is low, which leads to cell aging and death. The promoter’s mutations of the TERT gene are observed in 77% of the pecursor lesions of the melanoma and in a relatively early stage of their genesis, as well as in a large part of the cells of the melanoma itself. This leads to high telomerases activity, which prevents cell aging and apoptosis. The melanomas that cells have mutations in the TERT gene are accompanied with a poor prognosis [87].
Numerous cellular interactions, mediated by their cell adhesion molecules (cadherins and adherents) also play an important part in the pathogenesis of melanoma. The immune system also plays a significant role in the carcinogenesis of melanoma. Essential factors for anti-melanoma immunity are two types of immune response: humoral and cell-mediated. In order to survive, cancer cells can modify the immune response by employing several mechanisms such as reduction or deactivation of antigen presentation, immunological barriers in the tumour microenvironment, negative regulatory pathways in T cells, and T cell dysfunction [50,88,89]. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD1) are the two immune checkpoints that regulate immune homeostasis by inhibiting T cell activation. The development of monoclonal antibodies directed against CTLA-4 (ipilimumab) and PD1 (nivolumab, pembrolizumab), which eliminates the inhibition of T cell activity and restores the recognition ability of T cells, is a game-changer in the treatment of this disease; the development provides better treatment response and improved long-term survival [50]. These developments have become the gold standard for treatment in most patients with advanced and metastatic melanoma and are currently used in many other solid cancers and hematological malignancies [5,90,91].
A distinctive feature of the malignant neoplasms is their ability to disseminate and metastasize. Typically, melanocytes bind to basal keratinocytes through cell–cell adhesion molecules, such as the transmembrane glycoprotein E-cadherin. Loss of E-cadherin and upregulation of N-cadherin leads to the separation of melanoma cells from the epidermis and promotes melanoma invasion. Phosphatase and tensin homologue (PTEN) are suggested as potential regulators in the cell adhesion process [67,92].

4. Conclusions

This summary of the scientific data on the aetiology and pathogenesis of cutaneous melanoma is useful for understanding the basic features of melanoma, which is an important oncological entity. Despite significant recent progress in the management of this disease during the last couple of years, there is still a need for improvements in the prevention and the treatment of this deadly disease. Hopefully, this may result in the further reduction in the morbidity and the mortality of melanoma worldwide.

Author Contributions

Conceptualization, S.S.; writing—original draft preparation, S.S., A.Y.; writing—review and editing, S.S., A.Y.; visualization, S.S., A.Y.; supervision, S.S., A.Y.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Please refer to suggested Data Availability Statements in section “MDPI Research Data Policies” at https://www.mdpi.com/ethics.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Chin, L.; Merlino, G.; Depinho, R.A. Malignant melanoma: Modern black plague and genetic black box. Genes Dev. 1998, 12, 3467–3481. [Google Scholar] [CrossRef] [Green Version]
  2. Sayan, M.; Mamidanna, S.; Oncel, D.; Jan, I.; Vergalasova, I.; Weiner, J.; Ohri, N.; Acikalin, B.; Chundury, A. Clinical management of uveal melanoma: A comprehensive review with a treatment algorithm. Radiat. Oncol. J. 2020, 38, 162–169. [Google Scholar] [CrossRef]
  3. Jager, M.J.; Shields, C.L.; Cebulla, C.M.; Abdel-Rahman, M.H.; Grossniklaus, H.E.; Stern, M.H.; Carvajal, R.D.; Belfort, R.N.; Jia, R.; Shields, J.A.; et al. Uveal melanoma. Nat. Rev. Dis. Primers 2020, 6, 1–25. [Google Scholar] [CrossRef]
  4. Zheng, Y.; Cong, C.; Su, C.; Sun, Y.; Xing, L. Epidemiology and survival outcomes of primary gastrointestinal melanoma: A SEER-based population study. Int. J. Clin. Oncol. 2020, 25, 1951–1959. [Google Scholar] [CrossRef]
  5. Kahl, A.R.; Gao, X.; Chioreso, C.; Goffredo, P.; Hassan, I.; Charlton, M.E.; Lin, C. Presentation, Management, and Prognosis of Primary Gastrointestinal Melanoma: A Population-Based Study. J. Surg. Res. 2021, 260, 46–55. [Google Scholar] [CrossRef]
  6. Wohlmuth, C.; Wohlmuth-Wieser, I.; May, T.; Vicus, D.; Gien, L.T.; LaFramboise, S. Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients. Am. J. Clin. Dermatol. 2019, 21, 285–295. [Google Scholar] [CrossRef] [Green Version]
  7. Sun, X.; Gu, Y.; Xie, J.; Wang, L.; Zhou, Q. Melanoma of female genital tract: A clinicopathological analysis of 5 cases. Zhonghua Bing Li Xue Za Zhi 2020, 49, 834–836. [Google Scholar] [PubMed]
  8. Acikalin, A.; Bagir, E.; Karim, S.; Bisgin, A.; Izol, V.; Erdogan, S. Primary melanoma of the urinary tract; Clinicopathologic and molecular review of a case series. Pathol. Res. Pract. 2020, 216, 153095. [Google Scholar] [CrossRef] [PubMed]
  9. Kaboré, F.A.; Ouédraogo, B.; Ido, F.A.H.A.; Hafing, T.; Karama, H.; Traoré, O. Primary malignant melanoma of the urethra in women: About a case. Urol. Case Rep. 2021, 35, 101542. [Google Scholar] [CrossRef]
  10. Machado, A.K.L.P.; Nunes, D.B.C.; Carneiro, F.R.O.; Mendes, A.M.D. Primary melanoma of leptomeninge in a patient with giant congenital melanocytic nevus. An. Bras. Dermatol. 2020, 95, 404–406. [Google Scholar] [CrossRef] [PubMed]
  11. Cao, Y.; Wang, Y.-B.; Tan, X.-Y.; Cui, Y.-H.; Zhao, G. Multifocal primary amelanotic meningeal melanomas mimicking lymphoma: A case report and literature review. Br. J. Neurosurg. 2020, 15, 1–5. [Google Scholar] [CrossRef]
  12. Karimkhani, C.; Green, A.; Nijsten, T.; Weinstock, M.; Dellavalle, R.; Naghavi, M.; Fitzmaurice, C. The global burden of melanoma: Results from the Global Burden of Disease Study 2015. Br. J. Dermatol. 2017, 177, 134–140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kozmin, S.; Slezak, G.; Reynaud-Angelin, A.; Elie, C.; De Rycke, Y.; Boiteux, S.; Sage, E. Ultraviolet A radiation is highly mutagenic in cells that are unable to repair 7,8-dihydro-8-oxoguanine in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 2005, 102, 538–543. [Google Scholar] [CrossRef] [Green Version]
  14. Ichihashi, M.; Ueda, M.; Budiyanto, A.; Bito, T.; Oka, M.; Fukunaga, M.; Tsuru, K.; Horikawa, T. UV-induced skin damage. Toxicology 2003, 189, 21–39. [Google Scholar] [CrossRef]
  15. Carr, S.; Smith, C.; Wernberg, J. Epidemiology and Risk Factors of Melanoma. Surg. Clin. North Am. 2020, 100, 1–12. [Google Scholar] [CrossRef]
  16. Obrador, E.; Liu-Smith, F.; Dellinger, R.W.; Salvador, R.; Meyskens, F.L.; Estrela, J.M. Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. Biol. Chem. 2019, 400, 589–612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Douki, T. Oxidative Stress and Genotoxicity in Melanoma Induction: Impact on Repair Rather Than Formation of DNA Damage? Photochem. Photobiol. 2020, 96, 962–972. [Google Scholar] [CrossRef]
  18. Khan, A.Q.; Travers, J.B.; Kemp, M.G. Roles of UVA radiation and DNA damage responses in melanoma pathogenesis. Environ. Mol. Mutagenesis. 2018, 59, 438–460. [Google Scholar] [CrossRef]
  19. Trucco, L.D.; Mundra, P.A.; Hogan, K.; Garcia-Martinez, P.; Viros, A.; Mandal, A.; Macagno, N.; Gaudy-Marqueste, C.; Allan, D.; Baenke, F.; et al. Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma. Nat. Med. 2019, 25, 221–224. [Google Scholar] [CrossRef]
  20. Bishop, J. Lentigos, Melanocytic Naevi and Melanoma. In Rook’s Textbook of Dermatology, 8th ed.; Blackwell publishing: Oxford, UK, 2010; Volume 54, pp. 32–56. [Google Scholar]
  21. Trakatelli, M.; Bylaite-Bucinskiene, M.; Correia, O.; Cozzio, A.; De Vries, E.; Medenica, L.; Nagore, E.; Paoli, J.; Stratigos, A.J.; Del Marmol, V.; et al. Clinical assessment of skin phototypes: Watch your words! Eur. J. Dermatol. 2017, 27, 615–619. [Google Scholar] [CrossRef]
  22. Huang, J.M.; Chikeka, I.; Hornyak, T.J. Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence. Dermatol. Clin. 2017, 35, 85–93. [Google Scholar] [CrossRef] [Green Version]
  23. Damsky, W.; Bosenberg, M. Melanocytic nevi and melanoma: Unraveling a complex relationship. Oncogene 2017, 36, 5771–5792. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Loria, D.; Matos, E. Risk factors for cutaneous melanoma: A case-control study in Argentina. Int. J. Dermatol. 2001, 40, 108–114. [Google Scholar] [CrossRef] [PubMed]
  25. Stanganelli, I.; De Felici, M.B.; Mandel, V.D.; Caini, S.; Raimondi, S.; Corso, F.; Bellerba, F.; Quaglino, P.; Sanlorenzo, M.; Ribero, S.; et al. The association between pesticide use and cutaneous melanoma: A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 691–708. [Google Scholar] [CrossRef] [PubMed]
  26. Hausauer, A.; Swetter, S.; Cockburn, M.; Clarke, C. Increases in melanoma among adolescent girls and young women in California: Trends by socioeconomic status and UV radiation exposure. Arch. Dermatol. 2011, 147, 783–789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Raimondi, S.; Suppa, M.; Gandini, S. Melanoma Epidemiology and Sun Exposure. Acta Derm. Venereol. 2020, 100, 250–258. [Google Scholar] [CrossRef] [PubMed]
  28. De Vries, E.; Bray, F.; Coebergh, J.; Parkin, D. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int. J. Cancer 2003, 107, 119–126. [Google Scholar] [CrossRef]
  29. Dahl, C.; Guldberg, P. The genome and epigenome of malignant melanoma. Apmis 2007, 115, 1161–1176. [Google Scholar] [CrossRef]
  30. Sample, A.; He, Y.-Y. Mechanisms and prevention of UV-induced melanoma. Photodermatol. Photoimmunol. Photomed. 2018, 34, 13–24. [Google Scholar] [CrossRef]
  31. Ko, J.M.; Vélez, N.F.; Tsao, H. Pathways to Melanoma. Semin. Cutan. Med. Surg. 2010, 29, 210–217. [Google Scholar]
  32. Muñoz-Couselo, E.; Adelantado, E.Z.; Vélez, C.O.; Soberino-García, J.; Perez-Garcia, J.M. NRAS-mutant melanoma: Current challenges and future prospect. OncoTargets Ther. 2017, 10, 3941–3947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Cui, R.; Widlund, H.; Feige, E.; Lin, J.Y.; Wilensky, D.L.; Igras, V.E.; D’Orazio, J.; Fung, C.Y.; Schanbacher, C.F.; Granter, S.R.; et al. Central Role of p53 in the Suntan Response and Pathologic Hyperpigmentation. Cell 2007, 128, 853–864. [Google Scholar] [CrossRef] [Green Version]
  34. Pons, M.; Quintanilla, M. Molecular biology of malignant melanoma and other cutaneous tumors. Clin. Transl. Oncol. 2006, 8, 466–474. [Google Scholar] [CrossRef]
  35. Hima, P.; Yacoub, N.; Mishra, R.; White, A.; Long, Y.; Alanazi, S.; Garrett, J.T. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers 2020, 12, 482. [Google Scholar]
  36. Kim, M. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Small GTPases 2010, 1, 6222–6232. [Google Scholar] [CrossRef] [Green Version]
  37. Romano, C.; Schepis, C. PTEN Gene: A Model for Genetic Diseases in Dermatology. Sci. World J. 2012, 2012, 1–8. [Google Scholar] [CrossRef] [Green Version]
  38. Abdo, J.F.; Sharma, A.; Sharma, R. Role of Heredity in Melanoma Susceptibility: A Primer for the Practicing Surgeon. Surg. Clin. North Am. 2020, 100, 13–28. [Google Scholar] [CrossRef]
  39. Soura, E.; Eliades, P.; Shannon, K.; Stratigos, A.; Tsao, H. Hereditary Melanoma: Update on Syndromes and Management—Genetics of familial atypical multiple mole melanoma syndrome. J. Am. Acad. Dermatol. 2016, 74, 395–407. [Google Scholar] [CrossRef] [Green Version]
  40. Demierre, M.-F.; Sondak, V.K. Cutaneous melanoma: Pathogenesis and rationale for chemoprevention. Crit. Rev. Oncol. 2005, 53, 225–239. [Google Scholar] [CrossRef]
  41. Nikolaou, V.; Kang, X.; Stratigos, A.; Gogas, H.; Latorre, M.; Gabree, M.; Plaka, M.; Njauw, C.; Kypreou, K.; Mirmigi, I.; et al. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br. J. Dermatol. 2011, 165, 1219–1222. [Google Scholar] [CrossRef] [Green Version]
  42. Rebecca, V.; Sondak, V.; Smalleya, K. A brief history of melanoma: From mummies to mutations. Melanoma Res. 2012, 22, 114–122. [Google Scholar] [CrossRef] [Green Version]
  43. Sargen, M.; Merrill, S.; Chu, E.; Nathanson, K. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: A case series and review of the literature. Br. J. Dermatol. 2016, 175, 785–789. [Google Scholar] [CrossRef]
  44. Read, J.; Wadt, K.; Hayward, N. Melanoma genetics. J. Med. Genet. 2016, 53, 1–14. [Google Scholar] [CrossRef] [Green Version]
  45. Leachman, S.; Lucero, O.; Sampson, J. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 2017, 36, 77–90. [Google Scholar] [CrossRef] [Green Version]
  46. Newton-Bishop, J.; Bishop, D.; Harland, M. Melanoma Genomics. Acta Derm Venereol. 2020. [Google Scholar] [CrossRef]
  47. Dalmasso, B.; Ghiorzo, P. Evolution of approaches to identify melanoma missing heritability. Expert. Rev. Mol. Diagn. 2020. [Google Scholar] [CrossRef]
  48. Kearney, L.; Hogan, D.; Conlon, P.; Roche, M.; O’Neill, J.; O’Sullivan, J. High-risk cutaneous malignancies and immunosuppression: Challenges for the reconstructive surgeon in the renal transplant population. J. Plast. Reconstr. Aesthetic Surg. 2017, 70, 922–930. [Google Scholar] [CrossRef]
  49. Kubica, A.W.; Brewer, J.D. Melanoma in Immunosuppressed Patients. Mayo Clin. Proc. 2012, 87, 991–1003. [Google Scholar] [CrossRef] [Green Version]
  50. Konsoulova, A. Principles of cancer immunobiology and immunotherapy of solid tumors. In Immunopathology and Immunomodulation; Metodiev, K., Ed.; 2015; pp. 77–100. [Google Scholar]
  51. Ricci, F.; Paradisi, A.; Fania, L.; Pallotta, S.; Di Lella, G.; Sobrino, L.; Panebianco, A.; Abeni, D. High melanoma risk in non-melanoma skin cancer patients under age 40: A large retrospective cohort study. G. Ital. Dermatol. Venereol. 2019. [Google Scholar] [CrossRef]
  52. Banan, P.; Marvi, S.K.; McMeniman, E.; De’Ambrosis, B. An Australian cohort of 210 patients with multiple invasive squamous cell carcinomas: Risk factors and associated increased risk of melanoma and internal malignancies. Australas. J. Dermatol. 2015, 57, 29–32. [Google Scholar] [CrossRef]
  53. Sarangarajan, R.; Apte, S.P. The polymerization of melanin: A poorly understood phenomenon with egregious biological implications. Melanoma Res. 2006, 16, 3–10. [Google Scholar] [CrossRef]
  54. Meyskens, F.; Farmer, P.; Anton-Culver, H. Etiologic pathogenesis of melanoma: A unifying hypothesis for the missing attributable risk. Clin. Cancer Res. 2004, 15, 2581–2583. [Google Scholar]
  55. Elder, D.E.; Bastian, B.C.; Cree, I.A.; Massi, D.; Scolyer, R.A. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Arch. Pathol. Lab. Med. 2020, 144, 500–522. [Google Scholar] [CrossRef] [Green Version]
  56. Garbe, C.; Bauer, J. Melanoma. In Dermatology, 3rd ed.; Bolognia, J., Jorizzo, J., Schaffer, J., Eds.; Elsevier: Amsterdam, The Netherlands; Saunders: Philadelphia, PA, USA, 2012; Volume 2, pp. 1885–1914. [Google Scholar]
  57. Davies, M.; Garraway, L. Molecular biology of cutaneous melanoma. In Principles and Practice of Oncology; Devita, V., Hellman, T., Rosenberg, S., Eds.; Wolters Kluwer: Philadelphia, PA, USA, 2015; pp. 1337–1345. [Google Scholar]
  58. Cohen, J.; Sullivan, R. Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma. Clin. Cancer Res. 2019, 25, 5735–5742. [Google Scholar] [CrossRef] [Green Version]
  59. Leonardi, G.C.; Falzone, L.; Salemi, R.; Zanghì, A.; Spandidos, D.A.; Mccubrey, J.A.; Candido, S.; Libra, M. Cutaneous melanoma: From pathogenesis to therapy. Int. J. Oncol. 2018, 52, 1071–1080. [Google Scholar]
  60. Lo, J.; Fisher, D. Melanoma pathogenesis. In BRAF Targets in Melanoma; Sullivan, R., Ed.; Springer: New York, NY, USA, 2015; pp. 25–45. [Google Scholar]
  61. Sullivan, R.; Fisher, D. The Molecular Biology of Melanoma 2017. Available online: https://www.uptodate.com/contents/ (accessed on 12 June 2021).
  62. Kiuru, M.; Busam, K.J. The NF1 gene in tumor syndromes and melanoma. Lab. Investig. 2017, 97, 146–157. [Google Scholar] [CrossRef] [Green Version]
  63. Meng, D.; Carvajal, R.D. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. Am. J. Clin. Dermatol. 2019, 20, 315–323. [Google Scholar] [CrossRef] [PubMed]
  64. Czyz, M. HGF/c-MET Signaling in Melanocytes and Melanoma. Int. J. Mol. Sci. 2018, 19, 3844. [Google Scholar] [CrossRef] [Green Version]
  65. Williams, E.A.; Montesion, M.; Shah, N.; Sharaf, R.; Pavlick, D.C.; Sokol, E.S.; Alexander, B.; Venstrom, J.; Elvin, J.A.; Ross, J.S.; et al. Melanoma with in-frame deletion of MAP2K1: A distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Mod. Pathol. 2020, 33, 2397–2406. [Google Scholar] [CrossRef] [PubMed]
  66. Schadendorf, D.; Fisher, D.E.; Garbe, C.; Gershenwald, J.E.; Grob, J.J.; Halpern, A.; Herlyn, M.; Marchetti, M.A.; McArthur, G.; Ribas, A.; et al. Melanoma. Nat. Rev. Dis. Primers 2015, 1, 15003. [Google Scholar] [CrossRef]
  67. Roesch, A.; Volkenandt, M. Melanoma. In Dermatology, 3rd ed.; Braun-Falco, O., Plewig, G., Wolf, H., Burgdorf, W.H.C., Eds.; Springer: Berlin, Germany, 2009; pp. 1416–1432. [Google Scholar]
  68. Ballesteros-Álvarez, J.; Dilshat, R.; Fock, V.; Möller, K.; Karl, L.; Larue, L.; Ögmundsdóttir, M.H.; Steingrímsson, E. MITF and TFEB cross-regulation in melanoma cells. PLoS ONE 2020, 15, e0238546. [Google Scholar]
  69. Garraway, L.A.; Widlund, H.; Rubin, M.A.; Getz, G.; Berger, A.J.; Ramaswamy, S.; Beroukhim, R.; Milner, J.D.A.; Granter, S.R.; Du, J.; et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nat. Cell Biol. 2005, 436, 117–122. [Google Scholar] [CrossRef] [PubMed]
  70. Ugurel, S.; Houben, R.; Schrama, D.; Voigt, H.; Zapatka, M.; Schadendorf, D.; Bröcker, E.B.; Becker, J.C. Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response. Clin. Cancer Res. 2007, 13, 6344–6350. [Google Scholar] [CrossRef] [Green Version]
  71. Du, J.; Widlund, H.; Horstmann, M.A.; Ramaswamy, S.; Ross, K.; Huber, W.E.; Nishimura, E.K.; Golub, T.R.; Fisher, D.E. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004, 6, 565–576. [Google Scholar] [CrossRef] [Green Version]
  72. Levy, C.; Khaled, M.; Fisher, D.E. MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 2006, 12, 406–414. [Google Scholar] [CrossRef] [PubMed]
  73. Sherr, C.J. Principles of Tumor Suppression. Cell 2004, 116, 235–246. [Google Scholar] [CrossRef] [Green Version]
  74. Avery-Kiejda, K.A.; Bowden, N.A.; Croft, A.J.; Scurr, L.L.; Kairupan, C.F.; Ashton, K.A.; Talseth-Palmer, B.A.; Rizos, H.; Zhang, X.D.; Scott, R.J.; et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 2011, 11, 1–17. [Google Scholar] [CrossRef] [Green Version]
  75. Sirigu, P.; Piras, F.; Minerba, L.; Murtas, D.; Maxia, C.; Colombari, R.; Corbu, A.; Perra, M.T.; Ugalde, J. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: A comparison of two populations from different geographical regions. Eur. J. Histochem. 2006, 50, 191–198. [Google Scholar]
  76. Ragnarsson-Olding, B.; Platz, A.; Olding, L.; Ringborg, U. p53 protein expression and TP53 mutations in malignant melanomas of sun-sheltered mucosal membranes versus chronically sun-exposed skin. Melanoma Res. 2004, 14, 395–401. [Google Scholar] [CrossRef]
  77. Smalley, K.S.; Contractor, R.; Haass, N.K.; Kulp, A.N.; Atilla-Gokcumen, G.E.; Williams, U.S.; Bregman, H.; Flaherty, K.T.; Soengas, M.S.; Meggers, E.; et al. An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells. Cancer Res. 2007, 67, 209–217. [Google Scholar] [CrossRef] [Green Version]
  78. Onder, T.; Gupta, P.B.; Mani, S.; Yang, J.; Lander, E.S.; Weinberg, R.A. Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways. Cancer Res. 2008, 68, 3645–3654. [Google Scholar] [CrossRef] [Green Version]
  79. Wouters, B.G.; Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8, 851–864. [Google Scholar] [CrossRef]
  80. Bachmann, I.; Ladstein, R.; Straume, O.; Naumov, G.; Akslen, L. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 2008, 8, 1–10. [Google Scholar] [CrossRef] [Green Version]
  81. Chang, S.-H.; Worley, L.A.; Onken, M.; Harbour, J.W. Prognostic biomarkers in uveal melanoma: Evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 2008, 18, 191–200. [Google Scholar] [CrossRef]
  82. Hurlbut, G.D.; Kankel, M.W.; Lake, R.J.; Artavanis-Tsakonas, S. Crossing paths with Notch in the hyper-network. Curr. Opin. Cell Biol. 2007, 19, 166–175. [Google Scholar] [CrossRef]
  83. Balint, K.; Xiao, M.; Pinnix, C.C.; Soma, A.; Veres, I.; Juhasz, I.; Brown, E.J.; Capobianco, A.J.; Herlyn, M.; Liu, Z.-J. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J. Clin. Investig. 2005, 115, 3166–3176. [Google Scholar] [CrossRef]
  84. Hoek, K.; Rimm, D.L.; Williams, K.R.; Zhao, H.; Ariyan, S.; Lin, A.; Kluger, H.M.; Berger, A.J.; Cheng, E.; Trombetta, E.S.; et al. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas. Cancer Res. 2004, 64, 5270–5282. [Google Scholar] [CrossRef]
  85. Pinnix, C.C.; Lee, J.T.; Liu, Z.-J.; McDaid, R.; Balint, K.; Beverly, L.J.; Brafford, P.A.; Xiao, M.; Himes, B.; Zabierowski, S.E.; et al. Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes. Cancer Res. 2009, 69, 5312–5320. [Google Scholar] [CrossRef] [Green Version]
  86. Bedogni, B.; Warneke, J.A.; Nickoloff, B.J.; Giaccia, A.J.; Powell, M.B. Notch1 is an effector of Akt and hypoxia in melanoma development. J. Clin. Investig. 2008, 118, 3660–3670. [Google Scholar] [CrossRef] [Green Version]
  87. Shain, A.H.; Yeh, I.; Kovalyshyn, I.; Sriharan, A.; Talevich, E.; Gagnon, A.; Dummer, R.; North, J.P.; Pincus, L.B.; Ruben, B.S.; et al. The Genetic Evolution of Melanoma from Precursor Lesions. N. Engl. J. Med. 2015, 373, 1926–1936. [Google Scholar]
  88. Schadendorf, D.; Kochs, C.; Livingstone, E. Introduction to cutaneous melanoma. In Handbook of Cutaneous Melanoma—A Guide to Diagnosis and Treatment; Schadendorf, D., Kochs, C., Livingstone, E., Eds.; Springer Healthcare: New York, NY, USA, 2013; pp. 1–12. [Google Scholar]
  89. Lugović, L.; Situm, M.; Kos, L. Malignant melanoma--future prospects. Acta Dermatovenerol. Croat. ADC 2005, 13, 36–43. [Google Scholar] [PubMed]
  90. Sullivan, R.J.; Atkins, M.B.; Kirkwood, J.M.; Agarwala, S.S.; Clark, J.I.; Ernstoff, M.S.; Fecher, L.; Gajewski, T.F.; Gastman, B.; Lawson, D.H.; et al. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0. J. Immunother. Cancer 2018, 6, 1–23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  91. Weiss, S.A.; Wolchok, J.D.; Sznol, M. Immunotherapy of Melanoma: Facts and Hopes. Clin. Cancer Res. 2019, 25, 5191–5201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Lade-Keller, J.; Riber-Hansen, R.; Guldberg, P.; Schmidt, H.; Hamilton-Dutoit, S.; Steiniche, T. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Br. J. Dermatol. 2013, 169, 618–628. [Google Scholar] [CrossRef] [PubMed]
Ijms 22 06395 g001 550
Figure 1. Pigmented nevi.
Figure 1. Pigmented nevi.
Ijms 22 06395 g001
Ijms 22 06395 g002 550
Figure 2. MAPK pathway. NRAS—Neuroblastoma RAS viral oncogene homolog. BRAF—v-Raf murine sarcoma viral oncogene homolog B. MEK—Mitogen-activated protein kinase kinase. MAPK—Mitogen-activated protein kinase.
Figure 2. MAPK pathway. NRAS—Neuroblastoma RAS viral oncogene homolog. BRAF—v-Raf murine sarcoma viral oncogene homolog B. MEK—Mitogen-activated protein kinase kinase. MAPK—Mitogen-activated protein kinase.
Ijms 22 06395 g002
Ijms 22 06395 g003 550
Figure 3. PI3K/PTEN/AKT pathway. NRAS—Neuroblastoma RAS viral oncogene homolog. PI3—Phosphoinositol-3-kinase. PIP2—Phosphatidylinositol 4,5-bisphosphate. PIP3—Phosphatidylinositol (3,4,5)-trisphosphate. PTEN—Phosphatase and tensin homolog deleted on chromosome 10. AKT—Protein kinase B. mTOR—The mechanistic target of rapamycin. BCL-2—B-cell lymphoma-2. BAD—proapoptotic protein.
Figure 3. PI3K/PTEN/AKT pathway. NRAS—Neuroblastoma RAS viral oncogene homolog. PI3—Phosphoinositol-3-kinase. PIP2—Phosphatidylinositol 4,5-bisphosphate. PIP3—Phosphatidylinositol (3,4,5)-trisphosphate. PTEN—Phosphatase and tensin homolog deleted on chromosome 10. AKT—Protein kinase B. mTOR—The mechanistic target of rapamycin. BCL-2—B-cell lymphoma-2. BAD—proapoptotic protein.
Ijms 22 06395 g003
Table
Table 1. Risk factors for the development of cutaneous melanoma (cM).
Table 1. Risk factors for the development of cutaneous melanoma (cM).
Risk Factors Related to HumanRisk Factors Related to the Environment
Skin phototype
Pigmented nevi
Genetic factors
Heredity
Immunosuppressive conditions
Non-melanoma skin cancer		Ultraviolet radiation
Use of pesticides
Prolonged sun exposure and sunburn
Geographical location
Table
Table 2. Pathways for melanomas typically associated with cumulative solar damage.
Table 2. Pathways for melanomas typically associated with cumulative solar damage.
Melanomas Typically Associated with Cumulative Solar Damage
PathwayI
SSM/ low-CSD melanoma		II
LMM/ high-CSD melanoma		III
Desmoplastic melanoma
Benign
Neoplasms (nevi)		NevusIMP (?)IMP (?)
Intermediate
Neoplasms (low-grade dysplasias and melanocytomas)		1 Nevus with low-grade dysplasia;
2 BIN;
3 DPN		IAMP/dysplasia (?)IAMP/dysplasia (?)
Intermediate
neoplasms (high-grade dysplasias and melanocytomas)		1 Nevus with high-grade dysplasia/ MIS;
2 BAP1- inactivated melanocytoma/ MELTUMP;
3 Deep penetrating melanocytoma/ MELTUMP;
4 PEM/ MELTUMP		Lentigo maligna (MIS)MIS
Malignant neoplasms1 SSM(VGP); 2 Melanoma in BIN(rare); 3 Melanoma in DPN(rare); 4 Melanoma in PEM(rare);LMM (VGP)Desmoplastic melanoma
Common mutations1 BRAF p.V600 b; NRAS b; TERT d; CDKN2A a; TP53 a; PTEN a2 BRAF b; NRAS b + BAP1 a;
3 BRAF b; MAP2K1 b; NRAS b + CTNNB1 b; APC a;4 BRAF b +PRKAR1A a; RKCA c		NRAS b; BRAF non-p.V600E b; KIT b; NF1 a; TERT d; CDKN2A a; TP53 a; PTEN a; RAC1 bNF1 a; ERBB2 e; MAP2K1 e;
MAP3K1 e; BRAF e; EGFR e;
MET e; TERT d; NFKBIE d; NRAS b; PIK3CA b; PTPN11 b
Abbreviations: BIN, BAP1-inactivated nevus; CSD, cumulative solar damage; DPN, deep penetrating nevus; IAMP, intraepidermal atypical melanocytic proliferation; IMP, intraepidermal melanocytic proliferation without atypia; LMM, lentigo maligna melanom; MELTUMP, melanocytic tumor of uncertain malignant potential; MIS, melanoma in situ; PEM, pigmented epithelioid melanocytoma; SSM, superficial spreading melanoma; VGP, vertical growth phase (tumorigenic and/or mitogenic melanoma). a Loss-of-function mutation; b gain-of-function mutation; c rearrangement; d promoter mutation; e amplification. 1,2,3,4 Kinds of SSM/ low-CSD melanoma. (?) probable pathological type.
Table
Table 3. Pathways for melanomas that are not consistently associated with cumulative solar damage.
Table 3. Pathways for melanomas that are not consistently associated with cumulative solar damage.
Melanomas Not Consistently Associated with Cumulative Solar Damage
PathwayIV
Spitz melanoma		V
Acral melanoma		VI
Mucosal melanoma		VII
Melanomas arising in congenital nevi		VIII
Melanomas arising in blue nevi
Benign
neoplasms (nevi)		Spitz nevusAcral nevus (?)Melanosis (?)Congenital nevusBlue nevus
Intermediate
neoplasms (low-grade dysplasias and melanocytomas)		Atypica Spitz tumor melanocytoma)IAMPUS/dysplasiaAtypical melanosis
/dysplasia/IAMPUS		Nodul in congenital nevus (melanocytoma)(Atypical) cellular
blue nevus
(melanocytoma)
Intermediate
neoplasms (high -grade dysplasias and melanocytomas)		STUMP/ MELTUMPAcral MISMucosal MISMIS in congenital nevusAtypical cellular blue nevus
Malignant neoplasmsMalignant Spitz tumor/Spitz melanoma (tumorigenic)Acral melanoma (VGP)Mucosal lentiginous melanoma
(VGP)		Melanoma in
congenital nevus
(tumorigenic)		Melanoma in blue nevus (tumorigenic)
Common mutationsHRAS b; ALK e; ROS1 e; RET e; NTRK1 e; NTRK3 e; BRAF e; MET e; CDKN2A aKIT b; NRAS b; BRAF b; HRAS b; KRAS b; NTRK3 e; ALK e; NF1 a; CDKN2A a; TERT f; CCND1 d; GAB2 dKIT b; NRAS b; KRAS b; BRAF b; NF1 b; CDKN2A a; SF3B1 a; CCND1 d;
CDK4 d; MDM2 d		NRAS b; BRAF p.V600E b (small lesions); BRAF eGNAQ b; GNA11 b; CYSLTR2 b; BAP1 a; EIF1AX c; SF3B1c
Abbreviations: IAMPUS, intraepidermal atypical melanocytic proliferation of uncertain malignant potential; MELTUMP, melanocytic tumor of uncertain malignant potential; MIS, melanoma in situ; STUMP, spizoid tumor of uncertain malignant potential; VGP, vertical growth phase (tumorigenic and/or mitogenic melanoma). a Loss-of-function mutation; b gain-of-function mutation; c change-of-function mutation; d amplification; e rearrangement; f promoter mutation. (?) probable pathological type.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Strashilov, S.; Yordanov, A. Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. Int. J. Mol. Sci. 2021, 22, 6395. https://doi.org/10.3390/ijms22126395

AMA Style

Strashilov S, Yordanov A. Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. International Journal of Molecular Sciences. 2021; 22(12):6395. https://doi.org/10.3390/ijms22126395

Chicago/Turabian Style

Strashilov, Strahil, and Angel Yordanov. 2021. "Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances" International Journal of Molecular Sciences 22, no. 12: 6395. https://doi.org/10.3390/ijms22126395

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop